Psyence Group IncOTC Pink - Current Information:PSYGFView on Canadian Exchange
- LAST PRICE0.0119
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0119
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Oct 31, 2024
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs, from 9:30AM ET on Thursday Oct 31, 2024 by Dow Jones
9:30AM ET on Thursday Oct 31, 2024 by Dow JonesPress Release: Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs, from 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 25, 2024
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care, from 9:42AM ET on Friday Oct 25, 2024 by Dow Jones
9:42AM ET on Friday Oct 25, 2024 by Dow Jones
Oct 14, 2024
Press Release: Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical, from 10:43AM ET on Monday Oct 14, 2024 by Dow Jones
10:43AM ET on Monday Oct 14, 2024 by Dow JonesPsyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical, from 10:43AM ET on Monday Oct 14, 2024 by Dow Jones
10:43AM ET on Monday Oct 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Psyence Group Inc | 2.1M | --- | --- |
Company Information
Psyence Group Inc. is a Canada-based life science biotechnology company with a focus on natural psychedelics. The Company is focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. It cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its federally licensed ISO22000 facility in Southern Africa. The Company’s divisions include Psyence Production, Psyence Therapeutics and Psyence Function. Psyence Therapeutics develops natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment. Psyence Production operates federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world. Psyence Function is focused on the development, distribution and sale of over-the-counter functional mushroom nutraceutical products.
Contact Information
- Headquarters
- 121 Richmond Street West Penthouse Suite, 1300TORONTO, ON, Canada M5H 2K1
- Phone
- 416-477-1708
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 140.0M |
Psyence Group Inc does not pay a dividend. | |
Beta | 2.03 |
EPS | $-0.48 |
Book Value | $-0.17 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
